Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anatomy Of A Patent Dispute: Purdue Pharma’s OxyContin Battle

Executive Summary

Two years ago, Purdue Pharma's lawyers anxiously gathered together on a conference call. The U.S. Court of Appeals for the Federal Circuit had just issued its second opinion in OxyContin patent litigation. But the court's earlier ruling had accidentally been posted online. For a tense 20 minutes they waited until one of Purdue's outside attorneys got the final decision
Advertisement

Related Content

Patent Expiration May Not Help OxyContin Generics
At-Risk Launches: Three Cases May Determine How Damages Are Calculated
At-Risk Launches: Three Cases May Determine How Damages Are Calculated
Purdue Moves To Stave Off Branded, Generic Competitors To New OxyContin
Purdue Moves To Stave Off Branded, Generic Competitors To New OxyContin
Purdue Execs Plead Guilty To Misbranding OxyContin; Company Pays $700 Mil.
Purdue Execs Plead Guilty To Misbranding OxyContin; Company Pays $700 Mil.
Advertisement
UsernamePublicRestriction

Register

PS049373

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel